Format

Send to

Choose Destination
Nat Med. 2005 Nov;11(11):1170-2. Epub 2005 Oct 5.

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

Author information

1
Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph-Stelzmann-Strasse 9, D-50924 Cologne, Germany.

Abstract

We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.

PMID:
16205738
DOI:
10.1038/nm1319
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center